Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Experimental Therapeutics

Anidulafungin in Combination with Amphotericin B against Aspergillus fumigatus

Elisabetta Spreghini, Fiorenza Orlando, Alfredo Santinelli, Eleonora Pisa, Cristian Loretelli, Esther Manso, Maria Eleonara Milici, Giorgio Scalise, Francesco Barchiesi
Elisabetta Spreghini
1Dipartimento di Scienze Biomediche, Clinica Malattie Infettive
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fiorenza Orlando
4Dipartimento Ricerche Gerontologiche e Geriatriche N. Masera, I.N.R.C.A. I.R.R.C.S
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alfredo Santinelli
2Istituto di Anatomia Patologica
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eleonora Pisa
2Istituto di Anatomia Patologica
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cristian Loretelli
3Centro Regionale di Genetica Oncologica, Oncologia Medica, Università Politecnica delle Marche
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Esther Manso
5Laboratorio di Microbiologia Azienda Ospedaliero, Universitaria Ospedali Riuniti Umberto I°-Lancisi-Salesi, Ancona
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Eleonara Milici
6Dipartimento di Igiene e Microbiologia D'Alessandro, Università degli Studi di Palermo, Palermo, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giorgio Scalise
1Dipartimento di Scienze Biomediche, Clinica Malattie Infettive
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francesco Barchiesi
1Dipartimento di Scienze Biomediche, Clinica Malattie Infettive
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: f.barchiesi@ao-umbertoprimo.marche.it
DOI: 10.1128/AAC.00659-09
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • FIG. 1.
    • Open in new tab
    • Download powerpoint
    FIG. 1.

    Percentages of metabolic activity of three clinical isolates of A. fumigatus (F2, F3, and F4) at the stage of nongerminated conidia (A) and filamentous forms (B) detected by XTT assay. AFG (white bars), AMB (striped bars), and the combination of the two antifungal agents (black bars) were tested to concentrations of 1/4, 1, and 4 times the respective MICs and MECs. The bars represent the means of percent metabolic activity in the presence of the drugs with respect to the growth controls. The error bars indicate the standard deviations of the means. Letters a and b indicate reduced metabolic activity of the combination versus AFG and AMB alone, respectively (P < 0.05). Each strain was tested in triplicate.

  • FIG. 2.
    • Open in new tab
    • Download powerpoint
    FIG. 2.

    Survival of mice infected intravenously with the A. fumigatus F3 clinical isolate. In study 1, the animals were infected with 1.5 × 107 conidia/mouse and treated with AMB at 1 mg/kg/day, AFG at 1 mg/kg/day, and the respective combination regimen; in study 2, the mice were infected with 3.5 × 105 conidia/mouse and treated with AMB at 1 mg/kg/day, AFG at 1 mg/kg/day, and the respective combination; in study 3, the animals were infected with 3.2 × 106A. fumigatus conidia/mouse and treated with AMB at 0.5 mg/kg/day, AFG at 5 mg/kg/day, and the corresponding combination. The therapies were started 2 h postinfection (day 0) and continued through day 4 postinfection (five consecutive days). There were from 9 to 16 mice in each group. Asterisks indicate groups with prolonged survival over controls (due to multiple comparisons, P values of <0.016 were considered statistically significant).

  • FIG. 3.
    • Open in new tab
    • Download powerpoint
    FIG. 3.

    Histopathological sections of kidney and brain tissues stained with Grocott Gomori (original magnification, ×25) from mice infected with 3.2 × 106 conidia of the A. fumigatus F3 isolate. Representative histopathological sections of kidney and brain tissues from control mice (C) and from mice treated for three consecutive days with AMB at 0.5 mg/kg/day and AFG at 5 mg/kg/day are shown.

Tables

  • Figures
  • TABLE 1.

    In vitro susceptibility tests of AFG and AMB, alone and in combination, against three clinical isolates of A. fumigatusa

    IsolateDrug(s)MIC or MEC (μg/ml) at 24 hMIC or MEC (μg/ml) at 48 hMFC (μg/ml) at 48 h
    MedianRangeMedianRangeMedianRange
    F2AFG0.0010.001-0.0020.0020.002>16>16
    AMB0.50.25-0.51.01.01.01.0-2.0
    AFG + AMBb0.001/0.030.001-0.002/0.03-0.060.001/0.060.001-0.002/0.03-0.06<0.0002/1.0<0.0002/1.0-2.0
    F3AFG0.0010.001-0.0020.0020.002>16>16
    AMB0.250.25-0.51.00.5-1.01.00.5-1.0
    AFG + AMBb0.001/0.030.001/0.030.002/0.030.002-0.03<0.0002/1.0<0.0002/0.5-1.0
    F4AFG0.0020.001-0.0020.0020.002>16>16
    AMB0.250.125-0.51.01.0-2.01.00.5-1.0
    AFG + AMBb0.002/0.250.001-0.002/0.03-0.250.002/0.250.001-0.002/0.25<0.0002/1.0<0.0002/0.5-1.0
    • ↵ a Each test was run in triplicate and repeated on two different days.

    • ↵ b The MEC values were reported as end point readings of the checkerboard assays. The interaction between the drugs was classified as “indifferent” in each case (interactions were defined as synergistic if the FIC index was less than or equal to 0.50, indifferent if the FIC index was greater than 0.50 and less than or equal to 4.0, and antagonistic if the FIC index was greater than 4.0).

  • TABLE 2.

    Fungal burden in tissues of A. fumigatus-infected mice measured by CFU and quantitative PCR assaysa

    Challenge dose (conidia/mouse)Treatment (drug, dose [mg/kg/day])Brain burdenKidney burden
    Mean log10 CFU/g of tissue ± SDMean log10 CE/g of tissue ± SDMean log10 CFU/g of tissue ± SDMean log10 CE/g of tissue ± SD
    3.5 × 105Control3.17 ± 0.444.49 ± 0.355.12 ± 0.267.85 ± 0.57
    AMB, 12.51 ± 0.743.73 ± 0.814.74 ± 0.437.17 ± 0.64
    AFG, 13.02 ± 0.834.50 ± 1.094.95 ± 0.277.42 ± 0.59
    AMB, 1 + AFG, 13.06 ± 0.604.78 ± 0.474.89 ± 0.447.78 ± 0.53
    3.2 × 106Control3.73 ± 0.255.60 ± 0.365.31 ± 0.157.68 ± 0.22
    AMB, 0.53.82 ± 0.225.88 ± 0.714.96 ± 0.327.36 ± 0.34
    AFG, 54.08 ± 0.406.27 ± 0.654.60 ± 0.50*6.61 ± 0.66*
    AMB, 0.5 + AFG, 54.16 ± 0.716.58 ± 0.984.24 ± 0.39*6.50 ± 0.62*
    • ↵ a The animals were infected with the A. fumigatus F3 isolate (3.5 × 105 conidia/mouse and 3.2 × 106 conidia/mouse in studies 2 and 3, respectively) and euthanized 3 days later. There were seven animals per group, and fungal burdens of brains and kidneys were determined by measuring CFU or conidial equivalents (CE) per gram of tissue. Asterisks indicate treatment groups with reduced fungal burdens over the controls (due to multiple comparisons, P values of <0.016 were considered statistically significant).

PreviousNext
Back to top
Download PDF
Citation Tools
Anidulafungin in Combination with Amphotericin B against Aspergillus fumigatus
Elisabetta Spreghini, Fiorenza Orlando, Alfredo Santinelli, Eleonora Pisa, Cristian Loretelli, Esther Manso, Maria Eleonara Milici, Giorgio Scalise, Francesco Barchiesi
Antimicrobial Agents and Chemotherapy Aug 2009, 53 (9) 4035-4039; DOI: 10.1128/AAC.00659-09

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Anidulafungin in Combination with Amphotericin B against Aspergillus fumigatus
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Anidulafungin in Combination with Amphotericin B against Aspergillus fumigatus
Elisabetta Spreghini, Fiorenza Orlando, Alfredo Santinelli, Eleonora Pisa, Cristian Loretelli, Esther Manso, Maria Eleonara Milici, Giorgio Scalise, Francesco Barchiesi
Antimicrobial Agents and Chemotherapy Aug 2009, 53 (9) 4035-4039; DOI: 10.1128/AAC.00659-09
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

amphotericin B
antifungal agents
Aspergillus fumigatus
echinocandins

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596